Kura Oncology (NASDAQ:KURA) Share Price Crosses Below 50-Day Moving Average – Here’s Why

Kura Oncology, Inc. (NASDAQ:KURA)’s share price passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $9.45 and traded as low as $7.63. Kura Oncology shares last traded at $8.02, with a volume of 1,220,556 shares changing hands.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Leerink Partners set a $20.00 price target on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, UBS Group increased their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $28.00.

Kura Oncology Stock Up 2.3%

The business has a 50-day simple moving average of $9.45 and a two-hundred day simple moving average of $9.15. The company has a market cap of $697.90 million, a price-to-earnings ratio of -3.23 and a beta of 0.23. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02.

Insider Activity

In related news, insider Mollie Leoni sold 8,180 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $69,202.80. Following the completion of the sale, the insider directly owned 267,274 shares of the company’s stock, valued at approximately $2,261,138.04. This represents a 2.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Francis Burrows sold 23,726 shares of Kura Oncology stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $9.78, for a total transaction of $232,040.28. Following the completion of the transaction, the insider owned 33,735 shares in the company, valued at $329,928.30. This trade represents a 41.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 59,794 shares of company stock valued at $537,176. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. DRW Securities LLC bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $208,000. Insigneo Advisory Services LLC bought a new stake in Kura Oncology in the 4th quarter valued at $105,000. Renaissance Technologies LLC raised its stake in shares of Kura Oncology by 111.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock valued at $19,020,000 after buying an additional 965,256 shares in the last quarter. Alps Advisors Inc. lifted its holdings in shares of Kura Oncology by 83.3% during the 4th quarter. Alps Advisors Inc. now owns 71,447 shares of the company’s stock worth $742,000 after acquiring an additional 32,465 shares during the period. Finally, Sector Gamma AS lifted its holdings in shares of Kura Oncology by 4.0% during the 4th quarter. Sector Gamma AS now owns 455,841 shares of the company’s stock worth $4,736,000 after acquiring an additional 17,426 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.